Morgan Stanley Maintains Overweight on Kymera Therapeutics, Raises Price Target to $146

Benzinga · 5d ago
Morgan Stanley analyst James Quigley maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $135 to $146.